Walt Disney Co vs Smith & Nephew plc — how do they compare? Walt Disney Co trades at $103.28 (market cap $178.76B), while Smith & Nephew plc trades at $30.05 (market cap $12.54B). The key difference: Walt Disney Co is far larger — about 14.3× Smith & Nephew plc's market cap, and Smith & Nephew plc pays the higher dividend (2.65%). Which is the better fit depends on your goals.
| DIS | SNN | |
|---|---|---|
Market Cap | $178.76B | $12.54B |
Volume | 7,546,013 | — |
Sector | Media | Health |
52-Week High | $118.86 | $38.70 |
52-Week Low | $92.40 | $28.73 |
Enterprise Value | $219.62B | $15.57B |
Dividend Yield | 1.45% | 2.65% |
Signals from Pluang's Aura AI — not financial advice
Disney (DIS) trades at $103.20, down 1.62% on the day, amid a bullish technical signal and strong fundamental performance. The stock has consistently beaten earnings expectations in recent quarters, with Q2 2026 EPS of $2.06 exceeding estimates by $0.20. Revenue growth has been steady, reaching $94.43 billion in 2025, while net income surged to $12.40 billion. Analyst sentiment remains positive with a consensus price target of $126.00, representing a 22% upside. Recent news highlights advertising opportunities with major events like the Super Bowl and ongoing FCC regulatory challenges.
The outlook for Disney is favorable, driven by earnings momentum, strategic investments in parks and streaming, and a dominant position in entertainment. Key risks include regulatory disputes with the FCC, box office underperformance of recent films, and economic sensitivity. With a P/E of 21.35 and robust cash flow, the stock offers value for long-term investors despite near-term volatility.
No Aura AI signal available yet.
Trailing returns across standard periods
The Walt Disney Company is an entertainment company with operations in media networks, park experiences & consumer products, studio entertainment and Direct-to-Consumer networks and channels. The Company serves customers worldwide.
Read more on DIS →Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →